Clinical TrialMay 4, 2026, 05:02 PM
Telix TLX250-Px ZIRCON Data Highly Predictive for All Renal Malignancy
AI Summary
Telix Pharmaceuticals announced the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology. The analysis demonstrated that TLX250-Px (Zircaix®) PET/CT imaging may be highly predictive of renal malignancy across all subtypes, not limited to clear cell renal cell carcinoma (ccRCC). Positive PET findings showed a positive predictive value (PPV) of 98%, sensitivity of 82%, and specificity of 87% for malignancy overall, including non-clear cell renal cell carcinoma (nccRCC). These exploratory findings suggest broader applications for TLX250-Px beyond ccRCC detection and potential implications for nccRCC management.
Key Highlights
- New independent analysis of Phase 3 ZIRCON trial data for TLX250-Px published in European Urology.
- TLX250-Px PET/CT imaging is highly predictive of renal malignancy across all subtypes.
- Positive predictive value (PPV) of 98% (95% CI, 96 99) for malignancy overall.
- Sensitivity of 82% (95% CI, 82 90) and specificity of 87% (95% CI, 81 93) for malignancy.
- Exploratory findings suggest applications beyond clear cell RCC (ccRCC) to non-clear cell RCC (nccRCC).
- Essentially all false-positives for ccRCC in ZIRCON were other malignant kidney cancer subtypes.
- Original ZIRCON trial showed 86% sensitivity, 87% specificity, and 93% PPV for ccRCC.
Price Impact
More from TLX